GSK PLC ADR GSK

Morningstar Rating
Add To Portfolio
Market Closed
$41.03
1.03 | 2.58%
USD | New York Stock Exchange | Last close prices updated as of May 30, 2025, 7:45 PM EST | BATS BZX Real-Time Price
  • Last Close
    41
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • Investment Style
    Large Value
  • Market Cap
    83.2001 Bil
  • Forward Div Yield
    4.56%
  • Trailing Div Yield
    4.56%
  • Price/Sales
    1.78
  • Price/Book
    3.93
  • Beta (5-Year)
    0.55
  • Consensus Forward P/E
    7.81
  • Trailing 12-mo Rev
    31.53

Morningstar's Analysis

Valuation Oct 30, 2024
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
GSK Earnings: Strong Start to the Year Driven by Growth in Specialty Medicines
Author Photo
Jay Lee
Senior Equity Analyst
Analyst Note | by Jay Lee Updated May 01, 2025

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong growth in specialty medicines, which grew 17% and offset the 6% decline in the vaccines business.

Business Strategy and Outlook | by Jay Lee Updated Mar 27, 2025

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.

The magnitude of GSK's reach is evidenced by a product portfolio t

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

 
Price/Fair Value
Total Return %
Index Total Return %
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 YTD
0.04 2.02 -2.50 13.76 28.31 -17.33 25.81 -14.34 9.46 -4.54 23.77
0.37 17.15 13.16 -9.27 18.57 -11.45 18.43 1.25 7.75 9.94 9.18

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility